Protalix Biotherapeutics Inc (PLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $257.17M
Last updated: Nov 17, 2026 at 11:05 AM ET
Protalix Biotherapeutics Inc (PLX) Stock Forecast
Analysts expect Protalix Biotherapeutics (PLX) to earn $0.29 per share in the fiscal year ending Dec 31, 2026, on revenue of $87.25M. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.11.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 62.1% and revenue estimates fall 18.7%.
- Fiscal year ending Dec 31, 2026
- $0.29
- EPS consensus, revenue $87.25M
- Fiscal year ending Dec 31, 2027
- $0.11
- EPS consensus, revenue $70.95M
- Next report
- Mar 16, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.29 | $0.29 to $0.29 | 1 | $87.25M | $82.73M to $91.77M | 2 |
| Dec 31, 2027 | $0.11 | $0.11 to $0.11 | 1 | $70.95M | $69.22M to $72.68M | 2 |
Quarterly Estimates
The EPS consensus rises from -$0.02 for the quarter ending Dec 31, 2026 to $0.01 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.02 | -$0.04 to $0.01 | 3 | $12.98M | $9.31M to $17.01M | 3 |
| Mar 31, 2027 | $0.01 | $0.01 to $0.01 | 1 | N/A | N/A | 0 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 52.6% from $0.19.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.29 | $0.24 | $0.24 | $0.24 | $0.19 | +52.6% |
| Fiscal year ending Dec 31, 2027 | $0.11 | $0.05 | $0.05 | $0.05 | $0.06 | +100.0% |
| Quarter ending Mar 31, 2027 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0.0% |
Frequently Asked Questions About PLX
What is the PLX stock forecast?
Consensus analyst estimates put Protalix Biotherapeutics's EPS at $0.29 for the fiscal year ending Dec 31, 2026, on revenue of $87.25M.
What EPS do analysts expect from PLX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.29, with estimates from $0.29 to $0.29 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.11, with estimates from $0.11 to $0.11 from 1 analyst.
What revenue do analysts expect from Protalix Biotherapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $87.25M, with estimates from $82.73M to $91.77M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $70.95M, with estimates from $69.22M to $72.68M.
How many analysts cover PLX?
1 analyst estimates EPS for Protalix Biotherapeutics for the fiscal year ending Dec 31, 2026.
PLX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors